Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06649214
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-17
Brief Title:
A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Randomized Double-blind Double-dummy Positive Drug Parallel Controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to evaluate the safety and efficacy of olanzapine-samidorphan tablets in adults with schizophrenia The main questions it aims to answer are
question 1 Olanzapine-samidorphan significantly mitigate weight gain better than olanzapine
question 2 Olanzapine- samidorphan and olanzapine have similar antipsychotic efficacy
question 1 Olanzapine-samidorphan significantly mitigate weight gain better than olanzapine
question 2 Olanzapine- samidorphan and olanzapine have similar antipsychotic efficacy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None